- Exchange: NASDAQ GM
- Sector: Health Care
- Industry: Biotech & Pharma
- Sub-Industry: Specialty Pharmaceuticals
Snapshot for NuPathe Inc (PATH)
| Open: | 2.7201 | Day's Range: | 2.7000 - 2.8300 | Volume: | 77,109 |
|---|---|---|---|---|---|
| Previous Close: | 2.7800 | 52wk Range: | 2.4700 - 4.5900 | 1-Yr Rtn: | -12.81% |
Key Statistics for PATH
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -2.1100 |
| Est. EPS (USD) (12/2013) | -1.1400 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 86.69 |
| Shares Outstanding (M) | 31.07 |
| 30 Day Average Volume | 146,135 |
| Price/Book (mrq) | 5.2702 |
| Price/Sale (ttm) | - |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/14/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for PATH
Company Profile & Key Executives for PATH
NuPathe Inc. develops pharmaceutical products used for the treatment and management of neurological and psychiatric diseases. The Company offers various medicines for migraines, Parkinson's, schizophrenia, and other cognitive disorders.
| Armando AnidoChief Executive Officer | Terri B SebreePresident/Co-Founder |
| Keith Alan GoldanVP/CFO | Gerald W McLaughlin "Jerry"VP/Chief Commercial Officer |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
PATH News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page